Forskolin and ponatinib demonstrated a synergistic combination and mechanistic effect on BCR-ABL pathways that may reduce the progression of CML without the risk attributed to VAEs. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.